BLOG: Japan Patent Infringements for Generic and Biosimilar drugs

ELIQUENT Japan examines how a new proposal by Japan’s Ministry of Health, Labour, and Welfare may impact the system regulating patent infringements for generic and biosimilar drugs before they receive approval. Read the latest blog articleon IQ Central https://lnkd.in/enwDhhRG